Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ribociclib
Drug ID BADD_D02483
Description Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Indications and Usage Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.
Marketing Status Not Available
ATC Code L01EF02
DrugBank ID DB11730
KEGG ID D10883
MeSH ID C000589651
PubChem ID 44631912
TTD Drug ID D08MXP
NDC Product Code 0078-0874; 0078-0867; 0078-0860
Synonyms ribociclib | LEE011 | Kisqali
Chemical Information
Molecular Formula C23H30N8O
CAS Registry Number 1211441-98-3
SMILES CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pleural effusion22.05.02.0020.002664%
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumonitis22.01.01.0060.003197%
Polyneuropathy17.09.03.0120.000533%Not Available
Pruritus23.03.12.0010.008525%
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.0060.000278%
Pulmonary oedema22.01.03.003; 02.05.02.0030.001332%
Pulmonary tuberculosis22.07.06.002; 11.04.01.0030.000533%Not Available
Pyrexia08.05.02.0030.004795%
Rash23.03.13.0010.015452%Not Available
Rash erythematous23.03.06.0030.000799%Not Available
Rash generalised23.03.13.002--Not Available
Rash macular23.03.13.0030.001066%Not Available
Rash maculo-papular23.03.13.0040.000533%
Rash pruritic23.03.12.0020.001066%Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Red blood cell count decreased13.01.05.0070.000799%Not Available
Renal disorder20.01.02.0020.000799%Not Available
Renal failure20.01.03.005--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Rhinorrhoea22.02.05.0100.000799%
Second primary malignancy16.16.01.0140.000208%
Seizure17.12.03.001--
Sepsis11.01.11.003--
Sinusitis22.07.03.007; 11.01.13.0050.000799%
Skin discolouration23.03.03.0050.000799%Not Available
Skin exfoliation23.03.07.0030.001066%Not Available
Skin hypopigmentation23.05.02.0030.000533%
Sleep disorder19.02.04.001--Not Available
The 6th Page    First    Pre   6 7 8 9    Next   Last    Total 9 Pages